Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. KEYTRUDA ® is a ...
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback